Nature Communications (Oct 2018)
CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response
- Karol Szlachta,
- Cem Kuscu,
- Turan Tufan,
- Sara J. Adair,
- Stephen Shang,
- Alex D. Michaels,
- Matthew G. Mullen,
- Natasha Lopes Fischer,
- Jiekun Yang,
- Limin Liu,
- Prasad Trivedi,
- Edward B. Stelow,
- P. Todd Stukenberg,
- J. Thomas Parsons,
- Todd W. Bauer,
- Mazhar Adli
Affiliations
- Karol Szlachta
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- Cem Kuscu
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- Turan Tufan
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- Sara J. Adair
- Department of Surgery, University of Virginia School of Medicine
- Stephen Shang
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- Alex D. Michaels
- Department of Surgery, University of Virginia School of Medicine
- Matthew G. Mullen
- Department of Surgery, University of Virginia School of Medicine
- Natasha Lopes Fischer
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- Jiekun Yang
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- Limin Liu
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- Prasad Trivedi
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- Edward B. Stelow
- Department of Pathology, University of Virginia School of Medicine, Charlottesville
- P. Todd Stukenberg
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- J. Thomas Parsons
- Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine
- Todd W. Bauer
- Department of Surgery, University of Virginia School of Medicine
- Mazhar Adli
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine
- DOI
- https://doi.org/10.1038/s41467-018-06676-2
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
Predicting the response to chemotherapy is a major goal of cancer research. Here the authors use CRISPR knockout screens in pancreatic ductal adenocarcinoma cells to identify deletions synergistic with MEK inhibitors.
